Commencement of the CALCIO trial—designed to collect real-world data on the use of intravascular lithotripsy (IVL) with the Shockwave Medical IVL system in patients with chronic limb-threatening ischaemia (CLTI)—was the most-read Vascular News story in August.
1. CIRSE begins CALCIO trial enrolment for treatment of CLTI with Shockwave IVL system
The Cardiovascular and Interventional Society of Europe (CIRSE) has announced that patient enrolment for the CALCIO trial has begun. CALCIO started patient enrolment on 15 July 2024, with the goal of recruiting 400 chronic limb-threatening ischaemia (CLTI) patients over the next two years.
2. Claudication: Long-term Medicare study highlights “critical” need for value-based care
A newly published US Medicare cohort study illuminates trends and factors associated with peripheral vascular interventions (PVIs)—including a sharp rise in the use of ambulatory surgical centres (ASCs) and office-based laboratories (OBLs) for treatment—from 2011 to 2022.
3. Mitchell Silver joins Contego Medical as chief medical officer
Contego Medical recently announced that Mitchell Silver, an interventional cardiologist and vascular medicine specialist, has joined the team as chief medical officer (CMO).
4. SCOREPAD seeks to address “alarmingly high” mortality in CLTI patients with underlying coronary disease
A new research letter underscores the need to improve long-term survival following lower extremity revascularisation for chronic limb-threatening ischaemia (CLTI), setting out a randomised controlled trial to examine the impact of coronary artery ischaemia testing in these patients.
5. Physician-modified endografts “safe and effective” for thoracoabdominal and complex AAA repair
Researchers have reported a 94% technical success rate among other key findings from a recent international, multicentre, single-arm cohort study of physician-modified endografts (PMEGs) for thoracoabdominal and complex abdominal aortic aneurysm (AAA) repair. The work has been published in the American Heart Association (AHA) journal Circulation.
6. Centerline Biomedical receives US FDA 510(k) clearance for new IOPS Viewpoint catheter
Centerline Biomedical recently announced that its Intra-Operative Positioning System (IOPS) Viewpoint catheter has received US Food and Drug Administration (FDA) 510(k) clearance. The Viewpoint catheter is the most recent addition to the company’s patented IOPS portfolio.
7. New ESC guidelines combine peripheral arterial and aortic diseases for first time, emphasising interconnectivity of whole arterial system
The European Society of Cardiology (ESC) has published its 2024 guidelines for the management of peripheral arterial and aortic diseases (PAAD), evaluating these vascular conditions together as part of the same cardiovascular system.
8. InspireMD congratulates CREST-2 investigators on completion of trial enrolment
The CGuard embolic prevention stent system (EPS), utilising InspireMD’s MicroNet mesh, was included as a device option for stenting in the CREST-2 trials following US Food and Drug Administration (FDA) approval of the company’s investigational device exemption (IDE) supplement application in February 2022. CREST-2 included 23 cases implanted with CGuard.
9. Twelve-month STRIDE data show high limb salvage rate and quality of life improvement
One-year limb salvage and quality of life (QoL) data from the STRIDE study, showing that frontline use of Penumbra’s Indigo system for patients with lower extremity acute limb ischaemia (LE-ALI) is safe and effective, has been published in the Journal of Vascular Surgery. Results were presented at the Vascular Annual Meeting (VAM 2024; 19–22 June, Chicago, USA).
10. “Choosing the right devices for the right patients”: Surgeon-scientist secures NIH funding to develop MRI technique for precision PAD care
Michael Conte (San Francisco, USA) recently used his Veith Lecture at the 2024 Vascular Annual Meeting (VAM; 19–22 June, Chicago, USA) to call on young vascular surgeons on the peripheral arterial disease (PAD) frontlines to drive the space forward amid a great unmet need.
